Lonza Group company profile

LONN · SIX · CHF

Compare Lonza Group
CHF 663.00Change from previous close: −1.07%Absolute change: −CHF 7.20

Close · November 17, 2026

Company profile

Lonza Group has 20,141 employees and is headquartered in Basel, Switzerland.

Contract development and manufacturing for pharma and biotech companies forms the core of Lonza Group AG, which serves clients in Europe, North and Central America, Latin America, Asia, Australia and New Zealand. Its Integrated Biologics unit covers biologics services from clinical development through drug substance and drug product manufacturing, while Advanced Synthesis makes antibody-drug conjugates, related bioconjugates and potent active ingredients. The Specialized Modalities unit spans cell and gene, microbial, bioscience and mRNA technologies.

In the fiscal year ended December 2025, revenue reached CHF 6.5 billion, up 19.2% from the year before, while the company posted a net loss of CHF 275 million. It employed 20,141 people. Founded as a company incorporated in 1897, it is headquartered in Basel, Switzerland.

Company facts

Industry
Diagnostics & Research
Headquarters
Muenchensteinerstrasse 38, 4002, Basel
Employees
20,141
Chief executive
Wolfgang Wienand
Founded
1897
Fiscal year
January - December
Listing
LONN · SIX
Indices
SMI
Currency
CHF
ISIN
CH0013841017
Website
lonza.com

Lonza Group and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
Lonza GroupLONNSwitzerland$55.11B20,14123.5%43.9
Eurofins ScientificERFFrance$16.53B65,00014.1%30.5
bioMérieuxBIMFrance$11.7B14,56216.0%23.2
QiagenQIAGermany$10.3B5,40026.7%27.3
DiaSorinDIAItaly$4.56B3,21222.3%31.0
DiagnostykaDIAPoland$1.29B8,64514.9%20.3

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Lonza Group with its competitors